The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Martin HaluzíkGreg FulcherThomas R PieberLars BardtrumDeniz TutkunkardasHelena W RodbardPublished in: Diabetes, obesity & metabolism (2018)
IDegAsp retains a consistent safety and efficacy profile in patients with different baseline characteristics.
Keyphrases
- phase iii
- type diabetes
- body mass index
- blood glucose
- open label
- glycemic control
- clinical trial
- insulin resistance
- double blind
- phase ii
- placebo controlled
- blood pressure
- drug delivery
- obstructive sleep apnea
- physical activity
- weight gain
- randomized controlled trial
- case control
- sleep quality
- sleep apnea
- study protocol
- depressive symptoms
- adipose tissue
- metabolic syndrome
- weight loss